Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

34.33 +0.25 (+0.73%)
Streaming Delayed Price Updated: 9:58 AM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,684
Open 34.01
Bid (Size) 34.21 (100)
Ask (Size) 34.67 (200)
Prev. Close 34.08
Today's Range 33.99 - 34.89
52wk Range 17.72 - 44.28
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction ↗
Castle Biosciences (NASDAQ:CSTL) reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its... 
Via MarketBeat
News headline image
Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript ↗
Revenue hit $103.5 million, up 20% YoY, as TissueCypher surged 63%. 
Via The Motley Fool
Topics Earnings

Performance

YTD
-10.9%
-10.9%
1 Month
+40.5%
+40.5%
3 Month
+61.5%
+61.5%
6 Month
+11.4%
+11.4%
1 Year
+60.8%
+60.8%

More News

Read More
News headline image
Castle Biosciences Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Castle Biosciences (NASDAQ:CSTL) Surges After Smashing Q2 Estimates and Raising Guidance ↗
Via Chartmill
Castle Biosciences Inc (NASDAQ:CSTL) Beats Q1 Estimates, Raises Full-Year Guidance ↗
Via Chartmill
Castle Biosciences Inc (NASDAQ:CSTL) Reports Q4 2025 Revenue Beat Amid Profitability Transition ↗
Via Chartmill
News headline image
Castle (CSTL) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
This $56 Million Sale Slashed One Fund's DigitalBridge Stake Amid 49% Stock Surge ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
This Fund Just Disclosed a $29 Million Sale of a Beauty Stock Up 20% This Past Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What's Behind This $32 Million Bet on Baidu Amid a 36% Stock Rally? ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Regulatory Compliance
News headline image
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences (CSTL) Earnings Transcript ↗
Via The Motley Fool
News headline image
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares ↗
Via The Motley Fool
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
Via AB Newswire
Topics Intellectual Property
News headline image
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?
Yes, Castle Biosciences, Inc. - Common stock is publicly traded.
What exchange does Castle Biosciences, Inc. - Common stock trade on?
Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Castle Biosciences, Inc. - Common stock?
The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market
What is the current price of Castle Biosciences, Inc. - Common stock?
The current price of Castle Biosciences, Inc. - Common stock is 34.33
When was Castle Biosciences, Inc. - Common stock last traded?
The last trade of Castle Biosciences, Inc. - Common stock was at 08/27/26 09:58 AM ET
What is the market capitalization of Castle Biosciences, Inc. - Common stock?
The market capitalization of Castle Biosciences, Inc. - Common stock is 864.00M
How many shares of Castle Biosciences, Inc. - Common stock are outstanding?
Castle Biosciences, Inc. - Common stock has 864M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.